Prenatal Methamphetamine Exposure and Child Development in New Zealand and USA

新西兰和美国的产前甲基苯丙胺暴露与儿童发育

基本信息

批准号：
7915368
负责人：
LINDA L LAGASSE
金额：
$ 38.19万
依托单位：
WOMEN AND INFANTS HOSPITAL-RHODE ISLAND
依托单位国家：
美国
项目类别：
财政年份：
2007
资助国家：
美国
起止时间：
2007-09-05 至 2012-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7915368
关键词：
3 year old Administrative Supplement Affect Age-Months Alcohols Arousal Attenuated Belief Birth California Caregivers Characteristics Child Child Development Child Rearing Clinical Research Collaborations Communities Country Data Collection Development Drug Addiction Drug usage Environment Excision Extended Family Family Financial Support Frequencies Funding Hawaii Health Health Services Home environment Home visitation Hospitals House Call Infant Development International Intervention Iowa Knowledge Legal Life Style Longitudinal Studies Mandatory Reporting Measures Mediating Medical Methamphetamine Mothers National Institute of Drug Abuse Native-Born Neurosecretory Systems New Zealand Newborn Infant Oklahoma Outcome Outcome Study Parents Pharmaceutical Preparations Population Population Study Poverty Pregnancy Pregnant Women Problem behavior Protocols documentation Public Health Recruitment Activity Regulation Reporting Research Research Personnel Risk Factors Role Sample Size Sampling Site Social Policies Societies Substance abuse problem Sum Surveys Testing Visit Woman age group caregiving child poverty cohort evidence base fetal drug exposure fetal methamphetamine exposure follow-up foster care improved infant outcome methamphetamine exposure neurobehavioral prenatal prenatal exposure programs psychosocial response social social cognition statistics

项目摘要

DESCRIPTION (provided by applicant): This application is in response to PAS-03-023 International Research Collaboration on Drug Addiction. We had received an administrative supplement that added Auckland, New Zealand to our multisite Infant Development, Environment And Lifestyle (IDEAL) longitudinal study of the effects of prenatal methamphetamine (MA) exposure on child outcome. We have already established a Community Research Network (CRN) that includes four Clinical Research Partners (CRPs), from diverse study populations in Iowa, Oklahoma, California, and Hawaii where MA use by pregnant women is prevalent and where data collection for this 3-year longitudinal study is already underway. The supplement provided funds to recruit and conduct newborn and 1-month assessments of the New Zealand cohort. The purpose of this study is to extend the longitudinal follow up of the New Zealand cohort to 3 years. Recruitment in New Zealand is underway and 240 subjects with MA exposure and matched comparisons are anticipated. The longitudinal protocol of the proposed study includes annual visits at 1, 2, and 3 years and a home visit at 2.5 years. Measures of child include domains of arousal regulation, cognition, social relationships, neuromotor, neuroendocrine function, behavior problems and medical status. Measures of psychosocial risk factors include caregiving context and caregiver characteristics. We will test hypotheses related to the effects of prenatal MA exposure on child outcome when covariates including other drug use are controlled; hypotheses related to the role of psychosocial risk factors mediating effects of prenatal MA exposure on child outcome. The Auckland cohort will be analyzed separately and together with the larger IDEAL sample. With Auckland, New Zealand added to the IDEAL study as a fifth CRP, we will: (1) Increase the sample size of the IDEAL study; (2) Increase the observable effects of prenatal MA exposure on infant outcome by studying a group with less variability in the purity of MA and with a higher frequency of use than in other IDEAL sites; (3) Increase our understanding of the role of cultural childrearing and out-of-home placement issues, including social policy on the outcome of MA exposed children, and (4) Make an international contribution to our understanding of the effect of prenatal MA exposure on child outcome. The proposed study will advance our scientific understanding of this emerging problem and enhance our ability to develop appropriate interventions for these children.

描述（由申请人提供）：此申请响应PAS-03-023国际药物成瘾研究合作。我们收到了一种行政补品，将奥克兰，新西兰的奥克兰添加到我们的多站点婴儿的发育，环境和生活方式（理想）纵向研究，研究了产前甲基苯丙胺（MA）暴露对儿童结果的影响。我们已经建立了一个社区研究网络（CRN），其中包括四个临床研究伙伴（CRP），来自爱荷华州，俄克拉荷马州，加利福尼亚州和夏威夷的各种研究人群，孕妇的MA使用普遍存在，并且这项为期3年的纵向研究的数据收集了。该补品提供了对新西兰队列的新生儿和1个月评估的资金。这项研究的目的是将新西兰队列的纵向随访延长至3年。新西兰的招聘正在进行中，预计将有240名具有MA暴露和匹配比较的受试者。拟议的研究的纵向协议包括1年，2年和3年的年度访问和2。5年的家庭访问。儿童的度量包括唤醒调节，认知，社会关系，神经运动，神经内分泌功能，行为问题和医学状况的领域。心理社会风险因素的度量包括护理环境和照料者特征。当控制包括其他药物使用在内的协变量时，我们将检验与产前MA暴露对儿童结局的影响有关的假设；与心理社会危险因素介导产前MA暴露对儿童结局的作用的作用相关的假设。奥克兰队列将与更大的理想样本分开分析。在奥克兰，新西兰作为第五个CRP添加了理想的研究，我们将：（1）增加理想研究的样本量；（2）通过研究MA纯度较低且使用频率较高的群体比其他理想位点更高的群体来增加产前MA暴露对婴儿结局的可观察到的影响；（3）提高我们对文化育儿和户外安置问题的作用的理解，包括有关MA暴露儿童结果的社会政策，以及（4）国际贡献，以我们对产前MA暴露对儿童结果的影响的理解做出了贡献。拟议的研究将提高我们对这一新兴问题的科学理解，并增强我们为这些孩子开发适当干预措施的能力。